

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





www.rockland.com tech@rockland.com +1 484.791.3823

Datasheet for 009-001-T04S

PRKAR1B protein-HIS Epitope

Overview

Description:	PRKAR1B recombinant protein-HIS Epitope - 009-001-T04S
Item No.:	009-001-T04S
Size:	20 μg
Origin:	Human
Expressed in:	Sf9 cells

Product Details

Background:

PRKAR1B is the type I-beta regulatory subunit of cyclic AMP-dependent protein kinase A (PKA) which is an essential enzyme in the cAMP signaling pathway. PKA holoenzyme is composed of 2 regulatory and 2 catalytic subunits and dissociates from the regulatory subunits upon binding of cAMP. PKA controls many biochemical events in the cell including regulation of metabolism, ion transport, and gene transcription. PKA undergoes a dramatic conformational change upon complex formation with the catalytic subunit (1). PRKAR1B subunits can dimerize through an N-terminal motif and this dimerization is necessary for binding to PKA anchoring proteins (AKAPs) and targeting of PKA to its site of action. PRKAR1B Protein is ideal for investigators involved in Signaling Proteins, Cellular Proteins, Apoptosis/Autophagy, Cardiovascular Disease, ERK/MAPK Pathway, Inflammation, Invasion/Metastasis, Metabolic Disorder, Neurobiology, NfkB Pathway, and PKA/PKC Pathway research.

Synonyms:	PRKAR1, cAMP-dependent protein kinase type I-beta regulatory subunit
Species of Origin:	Human
Expressed in:	Sf9 cells
Туре:	Recombinant Protein

Target Details

Gene Name:	PRKAR1B
Purity/Specificity:	Recombinant full-length human PRKAR1B was expressed in Sf9 insect cells using a C-Terminal his epitope. The purity was determined to be >90% by densitometry.
Relevant Links:	• NCBI - NM 002735

www.rockland.com Page 1 of 3



www.rockland.com tech@rockland.com +1 484.791.3823

Application Details

Application Note:	PRKAR1B Protein is stored in 50mM sodium phosphate, pH 7.0, 300mM NaCl, 150mM imidazole, 0.1mM PMSF, 0.25mM DTT, 25% glycerol. PRKAR1B Protein is suitable for use in Western Blot. Expect a band approximately ~52kDa on specific lysates or tissues. Specific conditions for reactivity should be optimized by the end user.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
WB:	User Optimized

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	0.2 μg/μL
Buffer:	See application note.

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Expiration:	Expiration date is one (1) year from date of receipt.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

www.rockland.com Page 2 of 3





www.rockland.com tech@rockland.com +1 484.791.3823

www.rockland.com Page 3 of 3